{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for esketamine in Reference Text / Citation (approximate match)
Showing 1 - 2 of 2 results
Status:
US Approved Rx
(2019)
Source:
NDA211243
(2019)
Source URL:
First approved in 1970
Source:
NDA211243
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Esketamine is an S(+)-enantiomer of ketamine. It is a nonselective, noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptor. A nasal spray, containing esketamine, was approved in 2019 for the treatment of treatment-resistant depression in adults, in conjunction with an oral antidepressant, and is marketed under tradename SPARAVATO. Esketamine is a schedule III drug product in the USA.
Status:
US Approved Rx
(2019)
Source:
NDA211243
(2019)
Source URL:
First approved in 1970
Source:
NDA211243
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Esketamine is an S(+)-enantiomer of ketamine. It is a nonselective, noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptor. A nasal spray, containing esketamine, was approved in 2019 for the treatment of treatment-resistant depression in adults, in conjunction with an oral antidepressant, and is marketed under tradename SPARAVATO. Esketamine is a schedule III drug product in the USA.
